Meet the Newest Treatment for Autism Using Cannabidiol
Zynerba Pharma has just announced that the U.S. Patent and Trademark Office has issued a patent for the firm’s treatment of autism spectrum disorder with cannabidiol.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
With ever more states legalizing cannabis in the United States, it’s only a matter of time before it is legal across the country. After all, this drug does offer opportunities—outside of recreation—to treat serious diseases and conditions. Now, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has announced that the U.S. Patent and Trademark Office has issued a patent for the firm’s treatment of autism spectrum disorder (ASD) with cannabidiol (CBD).
This patent includes claims directed to methods of treating ASD by administering a therapeutically effective amount of synthetic CBD. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the company’s CBD product candidate, Zygel (ZYN002 transdermal CBD gel).
Note that this patent follows the previously announced issuance of the firm’s last patent, titled “Treatment of Fragile X Syndrome with Cannabidiol,” which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified CBD.
[nativounit]
The issuance of this patent comes as enrollment progresses in the open label Phase 2 Bright study evaluating the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with ASD. The efficacy assessments include the Aberrant Behavior Checklist, Parent Rated Anxiety Scale – Autism Spectrum Disorder, Autism Impact Measure and Clinical Global Impression – Severity and Improvement. The company expects to report top-line data in the first half of 2020.
Shares of Zynerba traded up about 7% Tuesday morning to $12.40, in a 52-week range of $2.75 to $16.47. The consensus price target is $20.08.
[recirclink id=553145]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
